Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.

CONCLUSIONS: An increase in CGP utilization from 2% to 10% among patients with advanced NSCLC undergoing molecular diagnostic testing was associated with modest budget impact, most of which was attributable to increased use of more effective treatments and prolonged survival. PMID: 30430885 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research